

Highlights of This Issue 1271

COMMENTARY

- 1273** The Myb-p300 Interaction Is a Novel Molecular Pharmacologic Target
Xi Liu, Kathryn A. Gold, and Ethan Dmitrovsky
See related article, p. 1276

SMALL MOLECULE THERAPEUTICS

- 1276** Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb by Blocking the Interaction with the KIX Domain of the Coactivator p300
Sagar Uttarkar, Sandeep Dukare, Bertan Bopp, Michael Goblirsch, Joachim Jose, and Karl-Heinz Klempnauer
See related commentary, p. 1273
- 1286** Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma
Deepti Soodgupta, Dipanjan Pan, Grace Cui, Angana Senpan, Xiaoxia Yang, Lan Lu, Katherine N. Weilbaecher, Edward V. Prochownik, Gregory M. Lanza, and Michael H. Tomasson
- 1295** CC-223, a Potent and Selective Inhibitor of mTOR Kinase: *In Vitro* and *In Vivo* Characterization
Deborah S. Mortensen, Kimberly E. Fultz, Shuichan Xu, Weiming Xu, Garrick Packard, Godrej Khambatta, James C. Gamez, Jim Leisten, Jingjing Zhao, Julius Apuy, Kamran Ghoreishi, Matt Hickman, Rama Krishna Narla, Rene Bissonette, Samantha Richardson, Sophie X. Peng, Sophie Perrin-Ninkovic, Tam Tran, Tao Shi, Wen Qing Yang, Zeen Tong, Brian E. Cathers, Mehran F. Moghaddam, Stacie S. Canan, Peter Worland, Sabita Sankar, and Heather K. Raymon
- 1306** Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101
Sahra Borges, Edith A. Perez, E. Aubrey Thompson, Derek C. Radisky, Xochiquetzal J. Geiger, and Peter Storz

LARGE MOLECULE THERAPEUTICS

- 1317** Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies
Hsin-Yi Tung, Yu-Cheng Su, Bing-Mae Chen, Pierre-Alain Burnouf, Wei-Chiao Huang, Kuo-Hsiang Chuang, Yu-Ting Yan, Tian-Lu Cheng, and Steve R. Roffler
- 1327** Recruitment of Oligoclonal Viral-Specific T cells to Kill Human Tumor Cells Using Single-Chain Antibody-Peptide-HLA Fusion Molecules
Roy Noy, Maya Haus-Cohen, Kfir Oved, Tali Voloshin, and Yoram Reiter
- 1336** Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer
Michele Mondini, Mevyn Nizard, Thi Tran, Laetitia Mauge, Mauro Loi, Céline Clémenson, Delphine Dugue, Pierre Maroun, Emilie Louvet, Julien Adam, Cécile Badoual, Dominique Helley, Estelle Dransart, Ludger Johannes, Marie-Catherine Vozenin, Jean-Luc Perfettini, Eric Tartour, and Eric Deutsch

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 1346** *CDKN2A/p16* Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans
Grant Eilers, Jeffrey T. Czaplinski, Mark Mayeda, Nacef Bahri, Derrick Tao, Meijun Zhu, Jason L. Hornick, Neal I. Lindeman, Ewa Sicinska, Andrew J. Wagner, Jonathan A. Fletcher, and Adrian Mariño-Enriquez
- 1354** The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression
Manali S. Phadke, Patrizia Sini, and Keiran S.M. Smalley
- 1365** $1\alpha,25$ -Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling
Ping-Tsung Chen, Ching-Chuan Hsieh, Chun-Te Wu, Tzu-Chen Yen, Paul-Yang Lin, Wen-Cheng Chen, and Miao-Fen Chen

Table of Contents

- 1376** CD30 Downregulation, MMAE Resistance, and *MDR1* Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Robert Chen, Jessie Hou, Edward Newman, Young Kim, Cecile Donohue, Xueli Liu, Sandra H. Thomas, Stephen J. Forman, and Susan E. Kane
- 1385** Blocking IL1 β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis
Tali Voloshin, Dror Alishekevitz, Limor Kaneti, Valeria Miller, Elina Isakov, Irena Kaplanov, Elena Voronov, Ella Fremder, Moran Benhar, Marcelle Machluf, Ron N. Apte, and Yuval Shaked
- 1395** Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells
Selvi Kunnimalaiyaan, Jose Trevino, Susan Tsai, T. Clark Gamblin, and Muthusamy Kunnimalaiyaan
- 1404** Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temezirolimus
Jennifer S. Carew, Claudia M. Espitia, Weiguo Zhao, Monica M. Mita, Alain C. Mita, and Steffan T. Nawrocki
- 1414** Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
Shigehiro Yagishita, Yu Fujita, Satoru Kitazono, Ryo Ko, Yusuke Nakadate, Takeshi Sawada, Yuka Kitamura, Tatsu Shimoyama, Yoshiharu Maeda, Fumiyouki Takahashi, Kazuhisa Takahashi, Tomohide Tamura, and Fumiaki Koizumi
- 1424** Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside–Nucleoside Analogue Radiosensitization
Simon Magin, Maria Papaioannou, Janapriya Saha, Christian Staudt, and George Iliakis
- 1434** Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of *MASTL* and *FOXM1* in NSCLC
Remco Nagel, Marijke Stigter-van Walsum, Marijke Buijze, Jaap van den Berg, Ida H. van der Meulen, Jasmina Hodzic, Sander R. Piersma, Thang V. Pham, Connie R. Jiménez, Victor W. van Beusechem, and Ruud H. Brakenhoff
- 1445** TR4 Nuclear Receptor Alters the Prostate Cancer CD133⁺ Stem/Progenitor Cell Invasion via Modulating the EZH2-Related Metastasis Gene Expression
Jin Zhu, Dong-Rong Yang, Yin Sun, Xiaofu Qiu, Hong-Chiang Chang, Gonghui Li, Yuxi Shan, and Chawnshang Chang
- 1454** MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NF κ B Activation in Breast Cancer
Sandra Muñoz-Galván, Gabriel Gutierrez, Marco Perez, and Amancio Carnero
- COMPANION DIAGNOSTICS AND CANCER BIOMARKERS**
- 1466** *PTEN* Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer
Duangmani Thanappapast, Rebecca A. Previs, Wei Hu, Cristina Ivan, Guillermo N. Armaiz-Pena, Piotr L. Dorniak, Jean M. Hansen, Rajesha Rupaimoole, Jie Huang, Heather J. Dalton, Rouba Ali-Fehmi, Robert L. Coleman, and Anil K. Sood
- 1476** Circadian Clock Gene *CRY2* Degradation Is Involved in Chemoresistance of Colorectal Cancer
Lekun Fang, Zihuan Yang, Junyi Zhou, Jung-Yu Tung, Chwan-Deng Hsiao, Lei Wang, Yanhong Deng, Puning Wang, Jianping Wang, and Mong-Hong Lee
- 1488** On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients
 Maria Schwaederle, Gregory A. Daniels, David E. Piccioni, Paul T. Fanta, Richard B. Schwab, Kelly A. Shimabukuro, Barbara A. Parker, and Razelle Kurzrock
- 1495** Enhanced *GAB2* Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition
Sally J. Davis, Karen E. Sheppard, Michael S. Anglesio, Joshy George, Nadia Traficante, Sian Fereday, Maria P. Intermaggio, Usha Menon, Aleksandra Gentry-Maharaj, Jan Lubinski, Jacek Gronwald, Celeste Leigh Pearce, Malcolm C. Pike, Anna Wu, Stefan Kommoss, Jacobus Pfisterer, Andreas du Bois, Felix Hilpert, Susan J. Ramus, David D.L. Bowtell, David G. Huntsman, Richard B. Pearson, Kaylene J. Simpson, Ian G. Campbell, and Kylie L. Goringe




Table of Contents

MODELS AND TECHNOLOGIES

1504 Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer

Wojciech Senkowski, Xiaonan Zhang, Maria Hägg Olofsson, Ruben Isacson, Urban Höglund, Mats Gustafsson, Peter Nygren, Stig Linder, Rolf Larsson, and Märten Fryknäs



AC icon indicates Author Choice

For more information please visit www.aacrjournals.org


CORRECTIONS

1517 Correction: Paclitaxel-Loaded PEG-PE-Based Micellar Nanopreparations Targeted with Tumor-Specific Landscape Phage Fusion Protein Enhance Apoptosis and Efficiently Reduce Tumors

1518 Correction: Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors

ABOUT THE COVER

Nitazoxanide, an FDA-approved antiparasitic agent, causes cell death in spheroids (indicated by the loss of GFP fluorescence), while cells in monolayer culture continue proliferating, as can be seen in the middle panels. In contrast, a standard chemotherapeutic agent, oxaliplatin, has a cytostatic effect in monolayer cells, while spheroids remain largely unaffected (bottom panels). For comparison, untreated controls are shown in top panels. For details, see the article by Senkowski and colleagues on page 1504.



Molecular Cancer Therapeutics

14 (6)

Mol Cancer Ther 2015;14:1271-1518.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/14/6>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/14/6>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.